|
1
|
Schiffer CA, Mangu PB, Wade JC, et al:
Central venous catheter care for the patient with cancer: American
Society of Clinical Oncology clinical practice guideline. J Clin
Oncol. 31:1357–1370. 2013.
|
|
2
|
Scappaticci FA, Skillings JR, Holden SN,
et al: Arterial thromboembolic events in patients with metastatic
carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer
Inst. 99:1232–1239. 2007.
|
|
3
|
Nalluri SR, Chu D, Keresztes R, et al:
Risk of venous thromboembolism with the angiogenesis inhibitor
bevacizumab in cancer patients: a meta-analysis. JAMA.
300:2277–2285. 2008.
|
|
4
|
Wells PS, Anderson DR, Rodger M, et al:
Derivation of a simple clinical model to categorize patients
probability of pulmonary embolism: increasing the models utility
with the SimpliRED D-dimer. Thromb Haemost. 83:416–420. 2000.
|
|
5
|
Aykan AC, Boyaci F and Hatem E: Successful
treatment of a pulmonary embolism with low dose prolonged infusion
of tissue typed plasminogen activator in a 37 year old female in
early postoperative period. Anadolu Kardiyol Derg. 14:400–402.
2014.
|
|
6
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342.
2004.
|
|
7
|
Kabbinavar FF, Schulz J, McCleod M, et al:
Addition of bevacizumab to bolus fluorouracil and leucovorin in
first-line metastatic colorectal cancer: results of a randomized
phase II trial. J Clin Oncol. 23:3697–3705. 2005.
|
|
8
|
Goldhaber SZ, Haire WD, Feldstein ML, et
al: Alteplase versus heparin in acute pulmonary embolism:
randomised trial assessing right-ventricular function and pulmonary
perfusion. Lancet. 341:507–511. 1993.
|
|
9
|
Chatterjee S, Chakraborty A, Weinberg I,
et al: Thrombolysis for pulmonary embolism and risk of all-cause
mortality, major bleeding, and intracranial hemorrhage: a
meta-analysis. JAMA. 311:2414–2421. 2014.
|
|
10
|
Stein PD and Matta F: Thrombolytic therapy
in unstable patients with acute pulmonary embolism: saves lives but
underused. Am J Med. 125:465–470. 2012.
|
|
11
|
Stein PD and Matta F: Treatment of
unstable pulmonary embolism in the elderly and those with comorbid
conditions. Am J Med. 126:304–310. 2013.
|
|
12
|
Kearon C, Kahn SR, Agnelli G, et al:
American College of Chest Physicians: Antithrombotic therapy for
venous thromboembolic disease: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). Chest.
133(Suppl 6): S454–S545. 2008.
|
|
13
|
Fiumara K, Kucher N, Fanikos J and
Goldhaber SZ: Predictors of major hemorrhage following fibrinolysis
for acute pulmonary embolism. Am J Cardiol. 97:127–129. 2006.
|
|
14
|
Mikkola KM, Patel SR, Parker JA, et al:
Increasing age is a major risk factor for hemorrhagic complications
after pulmonary embolism thrombolysis. Am Heart J. 134:69–72.
1997.
|
|
15
|
Thabut G, Thabut D, Myers RP, et al:
Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am
Coll Cardiol. 40:1660–1667. 2002.
|
|
16
|
Biteker M, Duran NE, Gündüz S and Ozkan M:
Treatment of pulmonary embolism with low-dose prolonged infusion of
tissue-type plasminogen activator in an 85-year-old woman. J Am
Geriatr Soc. 57:745–746. 2009.
|
|
17
|
Özkan M, Çakal B, Karakoyun S, et al:
Thrombolytic therapy for the treatment of prosthetic heart valve
thrombosis in pregnancy with low-dose, slow infusion of tissue-type
plasminogen activator. Circulation. 128:532–540. 2013.
|
|
18
|
Karavelioğlu Y, Karapınar H, Kucukdurmaz
Z, et al: Worm-like thrombus in the right heart treated with low
dose fibrinolytic therapy in a patient with pulmonary embolism.
Koşuyolu Heart Journal. DOI: 10.5578/kkd.5793. (Epub ahead of
print).
|
